Clinical trial
Oct 2026
Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis.
BACKGROUND Monoclonal antibodies targeting the interleukin-23 pathway are effective in treating inflammatory bowel disease. However, these therapies must be administered intravenously or by subcutaneous injection. METHODS We conducted a phase 2b, double-blind, randomized trial of oral icotrokinra, a peptide that bloc...
M. Abreu, B. Siegmund, L. Surace et al.
· New England Journal of Medic... · 0 citations